Our top pick for
Beginners

Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Enfusion, which produces Cloud-based investment management software, wrapped its IPO, selling 15.322 million shares at $17 per share, the high end of its announced price range.
Shares of Enfusion will begin trading on the NYSE later today under the ticker symbol ENFN, but shares are available for limit orders on Robinhood and other platforms.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
Latest market close | $10.47 |
---|---|
52-week range | $7.80 - $23.21 |
50-day moving average | $10.95 |
200-day moving average | $15.24 |
Wall St. target price | $13.50 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-3.05 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.47 from 2022-07-01
1 week (2022-06-24) | -6.68% |
---|---|
1 month (2022-06-03) | -5.25% |
3 months (2022-04-04) | -18.20% |
6 months (2022-01-04) | -47.17% |
1 year (2021-06-30) | N/A |
---|---|
2 years (2020-06-30) | N/A |
3 years (2019-06-30) | N/A |
5 years (2017-06-30) | N/A |
Revenue TTM | $121.5 million |
---|---|
Gross profit TTM | $79.9 million |
Return on assets TTM | -241.58% |
Return on equity TTM | -2085.37% |
Profit margin | -139.68% |
Book value | $0.84 |
Market capitalisation | $691.9 million |
TTM: trailing 12 months
We're not expecting Enfusion to pay a dividend over the next 12 months.
You may also wish to consider:
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.